Systematic review of pharmacological treatment options for orthostatic tremor in prospective patient cohorts and randomized controlled trials
Neurological Sciences · 2025
DOI: 10.1007/s10072-025-08129-3 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Neurological Sciences, 2025. Verfasst von Lena Sauthoff und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany. Hauptthemen laut MEDLINE: Tremor, Dizziness, Anticonvulsants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medizinische Hochschule Hannover (MHH).
Abstract (Originalsprache)
Introduction
Orthostatic tremor is an infrequent movement disorder characterized by a high-frequency tremor manifesting primarily in the standing position. This condition can lead to relevant restrictions of mobility in everyday life and adversely affect the quality of life. The etiology has not been conclusively clarified. To date, there are few therapy studies of sufficient quality.
Aim
The aim of the present literature analysis is to systematically evaluate the existing evidence of pharmacological therapies for orthostatic tremor. Materials and methods This study searched for publications via PubMed and Google Scholar using the terms “orthostatic tremor” AND “therapy” and “shaky legs syndrome” AND “therapy”. The main inclusion criteria were a subject number ≥ 5, pharmacological treatment approaches and the presence of a prospective experimental design.
Results
The evaluation of the results indicated the most positive evidence for therapy with gabapentin. Additionally, other drugs such as perampanel and levodopa also showed positive outcomes regarding specific endpoints. In contrast, there is a lack of evidence supporting the efficacy of levetiracetam and botulinum toxin in the context of primary orthostatic tremor. Discussion and conclusion According to current evidence, gabapentin is the drug with the most robust data. However, further studies are needed to support the evidence for different pharmacological therapeutic approaches for orthostatic tremor. Future investigations should emphasize larger sample sizes, placebo-controlled, double-blinded methodologies and a longer follow-up to be able to make more precise recommendations with greater generalizability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany.
- Department of Neurology, Vall d´Hebron Hospital, Paseo de la Vall d'Hebron, 119-129, Barcelona, 08035, Spain.
- Department of Neurology, Hannover Medical School, Carl-Neuberg-Straße 1, 30625, Hannover, Germany. Klietz.Martin@mh-hannover.de.
Förderung
- Medizinische Hochschule Hannover (MHH)
Zitieren
APA
Sauthoff, L., Achutegui, M. I., Ye, L., Niesmann, C., Wegner, F., Höllerhage, M., & Klietz, M. (2025). Systematic review of pharmacological treatment options for orthostatic tremor in prospective patient cohorts and randomized controlled trials. Neurological Sciences. https://doi.org/10.1007/s10072-025-08129-3
Vancouver
Sauthoff L, Achutegui MI, Ye L, Niesmann C, Wegner F, Höllerhage M, et al. Systematic review of pharmacological treatment options for orthostatic tremor in prospective patient cohorts and randomized controlled trials. Neurological Sciences. 2025. doi:10.1007/s10072-025-08129-3
BibTeX
@article{Sauthoff2025,
author = {Sauthoff, Lena and Achutegui, Maider Iza and Ye, Lan and Niesmann, Clara and Wegner, Florian and Höllerhage, Matthias and Klietz, Martin},
title = {Systematic review of pharmacological treatment options for orthostatic tremor in prospective patient cohorts and randomized controlled trials},
journal = {Neurological Sciences},
year = {2025},
doi = {10.1007/s10072-025-08129-3}
}
EUVIMED